Diabetes therapeutics such as glucose and weight control are major physiological functions of the new glucagon-like peptide-1 (GLP-1) agonists. But is there evidence to suggest that GLP-1 may also have some cardiovascular benefits? Join host Dr. Steven Edelman and Dr. John Buse, professor of medicine at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the emerging cardiovascular actions of incretin hormones.
Do Incretins Play An Important Role In the Cardiovascular System?

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Diabetes therapeutics such as glucose and weight control are major physiological functions of the new glucagon-like peptide-1 (GLP-1) agonists. But is there evidence to suggest that GLP-1 may also have some cardiovascular benefits? Join host Dr. Steven Edelman and Dr. John Buse, professor of medicine at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the emerging cardiovascular actions of incretin hormones.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
Pulmonary Hypertension Management: Practice Trends and Updates
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Evaluating Sleep Deprivation as a Risk Factor for Postpartum Depression
Clinical Strategies for Assessing Sleep Disturbances in Postpartum Patients
Reducing the Risk of Postpartum Depression Through Sleep Interventions
Diagnosing and Treating Benign Prostatic Hyperplasia and Overactive Bladder
Bladders, Breakthroughs, and Bold New Therapies: Key Updates at AUA 2025
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?